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INTRODUCTION 
In the United States otitis media is the most commonly diagnosed of 
childhood illnesses, next to the common cold."'" Occuring at an incidence 
of 10 to 17 percent yearly, the disease affects 76 to 95 percent of all 
2-5 
children at least once before age six. The disease is of such 
apparent ubiquity among pediatric populations that, as Paradise^ points 
out, otitis media figures preeminently in the differential diagnosis of 
fever, the management of pain, the prescribing of drugs, the pathogenesis 
of bacterial meningitis and other infections of the central nervous 
system, and the indications for the most frequently performed of 
childhood operations: tonsillectomy, adenoidectomy, and myringotomy 
with placement of tympanostomy tubes. Since the disease may be 
asymptomatic for long periods during infancy and childhood, hearing 
impairment may occur unnoticed, and the possible indirect effects 
of otitis media on cognitive, language, and emotional development 
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have become a serious health concern. ' 
Although the term otitis generically implies inflammation of some 
anatomic aspect of the human ear, otitis media refers specifically to 
an exudative disease manifest by the pathognomonic finding of fluid in 
the middle ear cavity. This fluid can represent either a suppurative 
or nonsuppurative disease process, but the distinction between the two 
classifications may be viewed as segments of a disease continuum - -
suppurative otitis being the usual immediate precursor of nonsuppurative 
otitis — without any demarcating event or differentiating physical 
finding.^ Because acute otitis media is often associated with a 
preexistent or coincident upper respiratory tract infection, the 
disease is predominantly of microbiologic cause. Streptococcus pneumoniae 
accounts for nearly 50 percent of the reported cases, Hernophilus 
influenzae for 25 percent, group-A streptococcus less than 5 percent, 
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and viral infection for less than 1 percent. ' 
The diagnosis of otitis media with effusion can be facilitated by 
the use of otoscopy, myringotomy, and needle aspiration of the middle 
ear. The advent of tympanometry has now equipped the clinician with 
an objective and noninvasive test to detect the presence of middle ear 
effus ion as well. The instruments used for this procedure direct a 
tone of fixed frequency into the ear canal and monitor physical 
properties of the resultant sound energy flow. Studies by several 
investigators have shown that the tympanogram, a graphical plot of 
sound energy flow with variation in the ear canal pressure has a 
high degree of diagnostic accuracy in detecting middle ear disease and, 
hence, represents an important tool in monitoring the course of the 
- . 9-16. pathologic process. 
Historically, therapy for otitis media has largely been aimed at 
eradication of the causative microbial agent and controlled clinical 
studies have demonstrated the efficacy of antiinfective drugs in 
treating this disorder. Adjunctive therapy has sometimes included the 
use of sympathomimetic and antihistaminic agents on the presumption 
19-21 
that these drugs will improve eustachian tube patency. The 
mechanism is not defined but one study suggests that by reduction of 
edema around the eustachian tube orifice, such as might result from 
a sympathomimetic drug, drainage from the middle ear to the nasopharynx 
19 
might be promoted and eustachian tube function restored. The 
value of these adjunctive agents has not been clearly demonstrated 
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clinically. This investigation was undertaken to determine the 
effectiveness of one antihistamine-decongestant product (Naldecon , 
Bristol Laboratories) in the treatment of acute otitis media with 
effusion when used in conjunction with the broad-spectrum antibiotic, 
amoxicillin (Polymox , Bristol Laboratories). 
METHODS 
Patient _Selection 
Seventy-nine patients were enrolled in the investigation. All 
were between the ages of seven months and fifteen years and all were 
selected from the patient population at the Willow Creek Pediatric 
Clinic, a private group-practice maintained by three pediatricians in 
Salt Lake City, Utah. The study was conducted between the months of 
October, 1979 and April, 1980 and the inducements for voluntary 
participation in the project were the provision of medications at no 
expense to the patient and the performance of complimentary tympanometric 
testing. 
Eligibility to enter the study was based on the clinical diagnosis 
of acute otitis media with effusion through history and physical examination 
as performed by the patient's personal pediatrician. Otitis media was 
diagnosed if the tympanic membrane was red and immobile to pneumatic 
otoscopy. Usually, it was thick and bulging as well. Documentation 
of middle ear effusion was made by tympanometry and application of the 
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criteria published by Beery and associates, discussed later in this 
section. A history of penicillin allergy, receipt of any antiinfective 
drug in the week prior to enrollment in the study, or a history of 
more than four episodes of otitis media in the previous year disqualified 
a volunteer from participation. 
Signs and symptoms compatible with the diagnosis of acute otitis 
media were construed to include earache, fever, visible drainage from 
the ear(s), "pulling" or digital manipulation of the ear(s), subjective 
reporting of extraneous ear sounds (e.g. "popping" or "ringing"), nasal 
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congestion, cough, listlessness, and irritability. These findings were 
noted by the investigators after interviewing the patients and their 
parents, and recorded along with other pertinent personal data in the 
patient's record. Written informed consent was obtained from each 
patient, parent, or guardian. 
Tympanometry 
9 
Following the methodology published by Shurin et al, bilateral 
tympanograms were studied and graphed by use of the Grason-Stadler 
Model 1720 Otoadmittance Meter supplied with a Model 1701 linear X-Y 
plotter (Grason-Stadler Company, Bolton, Massachusetts), calibrated 
according to the manufacturer's specifications and adjusted to give a 
rate of pressure change of 30 millimeters (mm) of water per second. 
Soft plastic probe tips of various sizes were used to occlude the ear 
canal during testing. The procedure caused no discomfort and required 
only that the subject not move excessively. Hand plots of the Tympanometry 
were made by the clinic audiologist if the patient's tracing was erratic 
due to artifact caused by movement. In performing tympanometry, plots 
of acoustic susceptance (B) and conductance (G) against ear canal pressure 
were recorded at two stimulus tone frequencies, 220 and 660 cycles 
per second (Hz). The recordings were made over a pressure range of -300 
to +200 mm of water in the direction of positive to negative pressure 
for B and negative to positive pressure for G. Figure 1 illustrates 
a tympanogram obtained from a normal child without any history of middle 
ear disease. 
To perform tympanometry with the otoadmittance meterr the probe of 
the instrument is placed in the entrance to external canal and isolated 
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from the surroundings by an airtight seal. This probe contains the 
ports of the three components of the meter (Figure 2). These components 
are a pump and manometer, which vary and measure the air pressure in 
the ear canal, an oscillator and loudspeaker, which supply tones of 
fixed frequency (either 220 or 660 Hz) and a microphone, which serves 
to detect the resultant sound energy flow. A feedback circuit is 
used to maintain the tone produced in the ear canal at a constant sound 
pressure of 85 decibels (dB). The sound transmission characteristics 
of the ear are altered by the varying hydrostatic stress placed upon 
the tympanic membrane by the pumping mechanism. Therefore, the constant 
85 dB sound pressure level in the ear canal must be maintained by 
variation in the current used to drive the loudspeaker. This current 
is relatively high in a normal ear with its efficient sound transmission 
into the middle ear. Conversely, the required current is relatively 
low when sound transmission from the ear canal is reduced, as occurs 
when effusion is present in the middle ear or when there are unequal 
pressures in the ear canal and middle ear. The root mean square (rms) 
voltage applied to the loudspeaker is monitored by the otoadmittance 
meter as a direct measure of acoustic admittance (Y) (Figure 3). The 
voltage monitored as a measure of Y may differ from that produced by 
the microphone not only in the magnitude of its vector but in the 
sine-wave phase of the two signals. One analyzes the variation in 
both magnitude and phase angle of these two signals by viewing Y as 
the resultant of the two separate vectors: G, the component that is 
in phase with the loudspeaker signal, and B, the component that is 
90 degrees out of phase. The otoadmittance meter measures the phase 
angle by which the loudspeaker and microphone signals differ by 
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multiplying the. two signals. The mean voltage of their product is a 
direct function of the phase angle; this angle with the value of 
admittance (Y) determines the respective values of acoustic conductance 
(G) and acoustic susceptance (B). The voltages measured are converted 
to millimhos (mmhos), the reciprocal of acoustic milliohms, by 
calibration of the unit with test chambers of 0.5 and 3.0 mmhos at 
220 Hz and 1.5 and 9.0 mmhos at 660 Hz. Calibration of the instrument 
for measurement of G is accomplished by temporary introduction of a 
90-degree phase shift into the G-meter circuit, with calibration in 
the same way as for B. 
For each tympanogram recorded, the audiologist analyzed the result 
on the basis of pattern classification, the location of the peak in 
relation to atmospheric pressure (mm water), and the height of the 
resultant wave peak (mmhos) measured relative to the baseline value 
at +200 mm water (Figures 1 and 4). 
Class III tympanograms were uniformly interpreted to mean the 
presence of effusion. For Class I patterns identified, if the susceptance 
at 660 Hz was less than 0.4 mmhos, the ear was considered to have 
effusion; if greater than 0.4 mmhos, the ear was considered dry. 
If a Class I, doubly peaked, trace was demonstrated at B660, 
the B220 trace was then evaluated and if at B220, the susceptance at 
peak compliance was less than 0.3 mmhos, effusion was present; if 
greater the ear was considered dry. All ears presenting as a Class IV 
pattern were considered suspect for effusion. 
Three certified audiologists from Primary Children's Medical 
Center in Salt Lake City, Utah were employed to perform and analyze 
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the tympanograms on an alternate day basis at the clinic. 
Additionally, following completion of the investigation, the 
audiologists independently reanalyzed all the tympanograms collected. 
After unanimously confirming the presence of middle ear effusion, they 
were also required to subjectively evaluate the appearance of each 
patient's series of tympanograms. Using their clinical judgement 
and a subjective criterion adapted from Paradise et al^ they noted 
if the tympanograms obtained at the trial's end represented a satisfactory 
or unsatisfactory measure of middle ear function relative to 
the patient's initial and mid-trial tympanograms. Disagreement with 
respect to the findings was settled by majority opinion. Satisfactory 
was interpreted to mean a peak pressure of between -100 and +50 
mm of water and a high peak compliance measured relative to the 
point on the horizontal axis at which the pressure was recorded. 
Unsatisfactory was interpreted to mean the presence of effusion, or 
a peak pressure of less than -100 mm of water and a low peak 
compliance. Flattened, Class III tympanograms were arbitrarily 
assigned a peak pressure of -400 mm of water for the purpose of 
mathematical computation. 
Drug Administration 
At the initial clinic visit of the patient, following confirmation 
of acute otitis media with effusion by the pediatrician, the patient 
was assigned to one of two treatment groups according to a random 
number table: 
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Treatment Group I (Naldecon Group); Received amoxicillin 
suspension (Polymox ) orally at between 20 and 50 mg/kg/day 
in three divided doses and Naldecon Syrup orally at a dose 
proportioned to deliver approximately 1 mg/kg/day phenylephrine, 
3 mg/kg/day phenylpropanolamine, 350 mcg/kg/day chlorpheniramine, 
and 1 mg/kg/day phenyltoloxamine in four divided doses. 
(Tables 1 and 2). 
Treatment Group II (Placebo Group): Received amoxicillin 
suspension (Polymox ) orally at between 20 and 50 mg/kg/day 
in three divided doses and placebo syrup (the inert vehicle 
for Naldecon , prepared by Bristol Laboratories) at a daily 
amount approximately equivalent to the volumes of Naldecon 
dispensed to Treatment Group I patients. 
The total duration of therapy with both drugs was fourteen days 
and the patients were discharged from the clinic with the exact amounts 
of medication necessary for the entire course of therapy. The drugs 
were dispensed solely by the principal investigators in six-ounce 
amber glass prescription bottles labeled in accordance with Utah State 
and Federal Pharmacy Laws. The bottles containing antihistamine-
decongestant and placebo were uniformly labeled as Naldecon Study Drug. 
Data Collection 
Data were collected during the course of three patient clinic 
visits which were seven days apart. 
At the initial visit the patient was examined by his/her personal 
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pediatrician and bilateral tympanograms were obtained by the audiologist. 
The physician and audiologist reviewed the tympanograms to determine if 
the patient had acute otitis media. The patients with otitis media and 
their parents were then interviewed by one of the investigators and a 
medical history and symptoms assessment were recorded. The appropriate 
medications were then dispensed. Additionally, the parent was given 
a diary and was requested to make daily entries for fourteen days in 
the diary pertinent to the patient's symptoms and drug compliance 
(Table 3). 
The patient returned to clinic on day seven of therapy. Bilateral 
tympanograms were again obtained. The patient and parent were interviewed 
by one of the investigators who reviewed the diary and measured the 
amounts of medication remaining in the bottles dispensed to assess 
compliance. Noncompliance was defined as the usage of less than 80 
percent of the total prescribed medication. 
On day fourteen of therapy the patient again returned to the clinic 
for bilateral tympanograms. The patient and parent were then interviewed 
by one of the investigators who recorded a final assessment of symptoms. 
The prescription bottles were collected to permit measurement of drug 
compliance and the daily diaries were obtained for analysis. The 
patient was then examined by his/her pediatrician who performed a 
final physical and otoscopic examination of the patient and evaluated 
the therapeutic response as satisfactory or unsatisfactory. By 
otoscopic examination, an unsatisfactory response was interpreted to 
mean the presence of a bulging or retracted tympanic membrane, an 
abnormally colored tympanic membrane, the visible presence of an air fluid 
level, or a poor degree of membrane mobility. A satisfactory response 
11 
was defined as the attenuation of all previously reported symptoms and 
a normal tympanic membrane by visual and pneumatic otoscopy. 
In order to preclude subjective biasing of the results, the 
audiologists and physicians were blinded and prevented from knowing the 
patients' treatment group assignments. 
Data Analysis 
The uniformity between the two treatment groups was analyzed by 
two standard statistical methods. Age of the patients and the number 
of episodes of acute otitis media in the preceding one year were evaluated 
by application of a two-tailed t-test for independent samples. Sex 
of the populations was compared by means of a chi-square analysis. 
Durations of earache, cough, and congestion were analyzed by 
recording the date at which the parent no longer reported the respective 
symptom in the daily diary and applying a two-tailed t-test for 
independent samples to the mean number of days the patient was symptomatic. 
Earache as a symptom was analyzed only for patients three years of age 
and older as it was felt that these individuals could reliably report 
such a complaint. 
A satisfactory or unsatisfactory therapeutic response as concluded 
by the physician was analyzed by tabulating the frequency of the 
respective conclusion in each of the treatment groups and applying 
a chi-square analysis. Similarly, the presence or absence of effusion 
in the two treatment groups as determined by tympanometry and the 
therapeutic response concluded by the audiologists was analyzed by the 
chi-square test. 
The number of patients in the two treatment groups who were 
12 
noncompliant with the prescribed medications were totaled and compared 
by application of a chi-square analysis. 
Tympanogram measurements for both the left and right ear collected 
over a two week period of time were analyzed by a split-plot analysis 
of variance for repeated measures on two or more treatments. The 
underlying research design which presupposes such an analysis, called 
a type SPF-p.qr design, has one between block-treatment (A) and two 
within block treatments (B,C). This design requires "np" samples of 
subjects who are randomly assigned to treatment A, with "n" subjects 
(blocks) in each level. The sequence of administration of the BC 
treatment combinations within an "np" block is randomized independently 
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for each subject. Figure 5 shows a block diagram of the design. 
Numerical computations were performed on the University of Utah's 
Univac 1100 computer employing an analysis of variance and covariance 
statistical package (BMDP2V) created at the University of California, 
Los Angeles. 
To test for significant data interaction, a correlational analysis 
incorporating forty variables was performed for all data. The Univac 
1100 computer employing a missing value correlation statistical analysis 
packet (BMDP8D) created at the University of California, Los Angeles was 
utilized. Table 4 summarizes the experimental variables included. 
Statistical significance was defined as p< 0.05 for all analyses 
performed. 
RESULTS 
Of the seventy-nine patients enrolled in the investigation, eleven 
were lost to follow-up, two were dropped due to severe worsening of 
their disease, and one was dismissed from the protocol because of the 
abrupt onset of extreme somnolence, dry mouth and blurred vision thought 
to be related to the administration of Naldecon . Other adverse 
reactions noted during the investigation were slight diarrhea in one 
patient possibly related to the use of amoxicillin, mild drowsiness in 
another patient, and extreme irritability in one child which promptly 
resolved upon reducing the Naldecon dosage by one-half. 
Complete bilateral tympanograms were obtained for sixty-five 
patients and personal diaries were collected from sixty-one, four 
patients having misplaced their copies. 
The Study Population 
Treatment Group I (Naldecon Group) was comprised of thirty 
patients: eleven males and nineteen females with a mean age of 32.7 + 
25.6 months. The mean number of episodes of acute otitis media for 
this group in the year prior to enrollment in the study was 1.8 + 2.1. 
All subjects had evidence of middle ear effusion by otoscopic exam. 
Tympanometry confirmed bilateral middle ear effusion in nineteen 
subjects, unilateral effusion in six, and it failed to confirm effusion 
in five. 
Treatment Group II (Placebo Group) was comprised of thirty-five 
patients: nineteen males and sixteen females with a mean age of 35.4 + 
25.4 months. The mean number of episodes of acute otitis media for 
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this group prior to enrollment in the study was 1.8 + 1.6. All patients 
had evidence of middle-ear effusion by otoscopic exam. By tympanometry 
fifteen patients had bilateral effusion, thirteen had unilateral 
effusion alone, and seven patients were without definite evidence for 
middle ear effusion. Two of these last mentioned patients did, however, 
have satisfactory criteria for unilateral effusion on day seven of 
their trial. 
For all biographical data analyses performed, there were no 
significant differences between the two groups and it was concluded 
that the patients .in the treatment sample groups were selected from 
one homogeneous patient population with a normal distribution (Tables 
5 and 6). 
Ancillary Symptoms 
Earache as a presenting complaint was reported by six patients in 
the Naldecon group and twelve patients in the placebo group. This 
symptom persisted for 2.5 + 1.5 days in the patients given the 
antihistamine-decongestant compared to 2.7 + 2.5 days reported by the 
placebo treated subjects (p>0.05) (Table 7). 
Cough as an initial complaint was reported by eighteen patients 
in the Naldecon group and twenty-four patients in the placebo group. 
Cough duration was 6 + 3 days in the Naldecon treated group and 
J.8 + 5 days in the placebo treated group (p>0.05) (Table 8). 
Twenty-four patients in the Naldecon group experienced nasal 
congestion as an initial ancillary complaint accompanying otitis media 
and thirty patients in the placebo group reported the same symptom. 
Following their enrollment in the investigation, the patients receiving 
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Naldecon remained congested for 5.7 + 3.8 days in contrast to the 
patients receiving placebo who had persistent congestion lasting 
8.5 + 4.9 days. Quantitatively, this difference was statistically 
significant (p<0.05) (Table 9) and suggested the efficacy of Naldecon 
in attenuating the nasal congestion accompanying otitis media with 
effusion. 
The presence of nasal congestion as a physical finding did not 
correlate with the initial presence of middle ear effusion as 
determined by tympanometry, nor did it correlate with the audiologists' 
evaluations of the tympanograms obtained on day seven of therapy. 
Congestion did, however, demonstrate a significant correlation with 
the presence of effusion confirmed by tympanometry in both the left 
ear (r = 0.31) and the right ear (r = 0.38) obtained on day fourteen 
of the trial which suggests that patients with persisting congestion 
were more likely to also have objective evidence for middle ear effusion 
at trial's end. Also apparent was a significant correlation between 
congestion and the physicians' evaluation of clinical response (r = 0.32) 
determined by final examination of the patient; as well as a significant 
correlation between congestion and the audiologists' assessment of 
whether the patients' final left ear tympanograms (r = 0.24) and right 
ear tympanograms (r = 0.33) were satisfactory or unsatisfactory. By 
these analyses, the physicians and audiologists were likely to conclude 
that patients with persisting congestion had responded unsatisfactorily 
to the prescribed drug regimen. 
Medication Compliance 
Defining noncompliance as the administration of less than 80 percent 
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of any of the prescribed medications, the two groups were not significantly 
different in their total drug consumption. In the Naldecon treated 
group, only three patients were noncompliant by this criterion: one 
patient missed six doses of Naldecon in the first week of the study 
and another missed six doses of Naldecon throughout week two; one 
patient failed to receive six doses of Naldecon in week two of his 
p 
therapy; and one patient completely omitted seven doses of Naldecon 
and five doses amoxicillin distributed over week two of her therapy. 
Only this last mentioned patient responded unsatisfactorily to her 
therapy as determined by tympanometric criteria for bilateral effusion 
and otoscopic exam. 
In the placebo treated group, one patient failed to receive six 
doses of placebo in the second week of her therapy, and another 
patient missed nine doses. Only one patient was noncompliant with 
her antibiotic, missing four doses of amoxicillin throughout the second 
week of therapy. All three patients had unsatisfactory responses by 
the physicians' evaluation and two patients had tympanometric criteria 
for bilateral middle ear effusion still evident at day fourteen. The 
results are summarized in Table 10. 
Correlational analysis performed for total amounts of all medications 
omitted by all patients and therapeutic outcome failed to reveal a 
significant relationship for all analyses performed. Table 11 
summarizes the results. 
Tympanogram Classification 
Analysis of the classification of all tympanograms obtained at the 
initial, second, and final clinic visits revealed the repetitive 
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identification of class I and III tympanograms, with class II and 
IV tympanograms being conspicuously absent. 
Initially, the number of patients presenting with class I and III 
tympanograms was identical for both groups (Table 12). Tympanograms 
obtained upon the patients' return to clinic on day seven revealed only 
minor change in the classification of the ears relative to day one. 
The difference between the groups at day seven was not significant 
(p>0.05) (Table 13). Analysis of the final tympanograms obtained 
on day fourteen of the trial again showed only minor change from the 
tympanograms at day seven, and between groups this difference was 
not statistically significant (p> 0.05) (Table 14). 
Tympanometric Criteria for Effusion 
As Table 6 demonstrates, 83.3% (25/30) of the patients in the 
Naldecon group and 80% (28/35) of the patients in the placebo group 
had tympanometric criteria for middle ear effusion upon entry into the 
study. There was no significant difference between the two groups 
with respect to left or right ear involvement (p>0.05) (Table 15). 
Repeat tympanograms obtained at day seven of therapy demonstrated 
that effusion had started to resolve in both groups, however, the 
difference between groups was not statistically significant (p>0.05). 
46.7% of the Naldecon^ treated patients (14/30) and 54.3% of the placebo 
treated patients (19/35) had tympanometric criteria for effusion (Table 16). 
The frequency distribution for left and right ear involvement is illustrated 
in Table 17. 
On day fourteen of the investigation, tympanometry revealed that 
resolution of middle ear effusion had occured relative to day one. 
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Although 26.7% (8/30) of the Naldecon group still met criteria for 
effusion in contrast to 48.6% (17/35) of the placebo group, this result 
emphasized that 73.3% (22/30) of the Naldecon treated patients were 
devoid of effusion while only 51.4% (18/35) of the placebo treated 
patients were effusion-free at day fourteen (p = 0.07). Additional 
examination of the frequency distribution of effusion in the two 
treatment groups reveals that the presence of left middle ear effusion 
was not significantly different between groups, but there was a 
significant difference for the frequency of right middle ear effusion. 
Of the right ears tested in the Naldecon group, 20% (6/30) had 
effusion compared to 45.7% (16/35) of the right ears tested in the placebo 
group (p<0.05). The results are illustrated in Tables 18 and 19. 
The audiologists' final subjective evaluation of the tympanograms did 
not necessarily corroborate these findings. Their conclusions regarding 
the satisfactoriness of the tympanograms obtained at day fourteen revealed 
that 66.7% (20/30) of the Naldecon treated patients had satisfactory 
bilateral tympanograms compared to 48.6% (17/35) of the placebo treated 
patients (p>0.05). The results are illustrated in Table 20. 
The physicians' final evaluation of therapeutic response failed to 
confirm a significant difference in outcome for patients assigned to 
either the antihistamine-decongestant or placebo treatment groups. 
Sixty-three and a third percent (19/30) of the Naldecon patients and 
54.3% (19/35) of the placebo patients had satisfactory responses by 
clinical criteria to the prescribed course of management (p>0.05). Of 
the NaldeconR treated patients, 36.7% (11/30) compared to 45.7% (16/35) 
of the placebo treated patients were evaluated as unsatisfactory and 
required further follow-up or extension of their treatment with 
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alternative antibiotics (Table 21). 
The relationship between the physicians' evaluation of therapeutic 
response and the presence of effusion as determined by tympanometry was 
statistically significant. Clinical examination correlated well with 
both left ear effusion at day fourteen (r = 0.52) and right ear effusion 
(r = 0.45), implying that patients with middle ear effusion at day 
fourteen were also likely to be evaluated as unsatisfactory responders 
to their particular regimen. 
The physicians' final examination also correlated well with the 
audiologists' analyses of the left and right ear tympanograms obtained 
on the final day of the trial (r = 0.52), emphasizing that both groups 
of practitioners agreed in their final analyses. 
By the analysis of variance performed for all tympanogram 
measurements obtained over fourteen days, it was apparent that time had 
a significant effect on the middle ear pressure measurements (p<0.05) 
and the middle ear compliance measurements (p<0.05) for both groups 
(i.e. all ear measurements changed as a function of time), but the 
contribution of other data interactions did not approach statistical 
significance. The results are summarized in Tables 22 and 23. 
Therapeutic Outcome and Population Characteristics 
By correlational analysis, therapeutic outcome as determined by the 
physicians' examination, the presence or absence of tympanometric criteria 
for middle ear effusion, and the audiologists' evaluation of the final 
tympanograms was unaffected by the age and sex of the patient, and the 
number of episodes of acute otitis media experienced by the patient in 
the preceding one year. Table 24 summarizes the results. 
DISCUSSION 
Although the pathogenesis of otitis media with effusion remains 
unclear, there is increasing evidence to suggest that it is related 
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to abnormal function of the eustachian tube. 
In the normal ear the eustachian tube is functionally obstructed 
or collapsed at rest with a consequent slight negative pressure existing 
in the middle ear. Intermittent active opening of this tube by the 
tensor veli palatini muscle serves to maintain near-ambient pressures 
in the middle ear cavity and nourish the lining mucosa with a continuous 
25 26 
supply of air. ' The eustachian tube also serves to protect the 
middle ear from nasopharyngeal sound pressure and accumulated secretions. 
In some cases, in which active forces alone are inadequate to override 
eustachian tubal resistance, the interval between openings depends 
on the establishment of a pressure gradient between the middle ear 
25 
cavity and the nasopharynx which passively assists tubal function. 
Physiologically, this gradient results from the progressive negative 
middle ear pressure caused by local absorption of middle ear gas and 
although this pressure gradient represents normal variant, the 
existence of periodic or persistent high negative pressure can be 
pathologic and has been associated with abnormal eustachian tube 
25 27 
function. ' If ventilation occurs at a time of high negative 
middle ear pressure, aspiration of nasopharyngeal secretions into the 
middle ear could occur and precipitate an episode of otitis media 
25 
with effusion. Whether middle ear infection - - distinct from 
sterile inflammation - - can occur in the absence of preexisting 
eustachian tube dysfunction due to obstruction, however, remains unknown. 
Obstruction of the eustachian tube could ostensibly result from a 
number of causes: extraluminally, from hypertrophic nasopharyngeal 
lymphoid tissue, or tumor; intraluminally, from inflammatory edema of 
the tubal mucosa; or intramurally, from impairment of the opening 
mechanism of the tube, secondary to poor muscle function or excessive 
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tubal wall compliance, or both. It is thought that functional, 
intramural obstruction of the tube appears to be the most common type 
of occlusion found in children with otitis media with effusion. 
Nasal obstruction, such as that which occurs in the course of an 
upper respiratory tract infection, may also be involved in the 
pathogenesis of otitis media with effusion. Swallowing when the nose 
is obstructed (due to inflammation or obstructive adenoids) results in 
an initial positive nasopharyngeal air pressure, followed by a negative 
pressure phase. In a compliant tube, secretions might be insufflated 
into the middle ear with a positive nasopharyngeal pressure, especially 
when the middle ear has a high negative pressure; or with negative 
nasopharyngeal pressures, such a tube could be prevented from opening 
25 
and be further obstructed functionally. 
Obstruction of the eustachian tube as a preceding or accompanying 
event to otitis media with effusion has provided the basis for this 
investigation. The possibility that relief of this obstruction might 
be achieved by pharmacologic means and thereby promote resolution of 
the middle ear pathology has been examined by us, as well as other 
independent researchers. 
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In 1970, Miller compared an oral antihistamine-decongestant 
mixture with placebo for effects on eustachian tube function in 
thirteen children with chronic serous otitis media and tympanostomy 
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tubes. He inflated the balloon of a foley catheter in the external ear, 
connected it to a two milliliter precision syringe and artificially 
induced pressure changes in the middle ear. If the induced pressure 
was relieved through the eustachian tube, the pressure change was 
sensed by a transducer and recorded. In a double-blind crossover 
study, five children responded with an improved patency to the oral 
decongestant, four children showed no response, and four children 
had a suggestIve response. None of the thirteen patients responded 
to the placebo. Four patients apparently had a history of nasal 
allergy and houce, the author concluded that the oral decongestants might 
benefit some children with serous otitis media, particularly those 
with allergic rhinitis. 
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Rubenstein and associates treated 462 cases of acute otitis media 
in children villi combinations of antibiotics and pseudoephedrine. The 
authors concluded that the addition of an oral decongestant had no effect 
on the rate of failures, recurrence, or residual effects measured by 
audiometric evaluations. They did not, however, specifically measure 
the effects of pseudoephedrine on eustachian tube function. 
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Stickler and associates treated 514 episodes of acute otitis media 
with combinativ>ns of penicillin, triple sulfonamide, and an antihistamine. 
Fifteen and a half percent of the patients had a history of allergic 
rhinitis or tu-iv fever. A lower failure rate was noted in those patients 
given the antihistamine, although for reasons not understood by the 
authors. 
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In 1978, Olson and associates studied the efficacy of an oral 
decongestant in preventing and treating serous otitis media in 192 
cases of acute otitis media. Otitis media was diagnosed and monitored 
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by pneumatoscopy and tympanic membrane mobility testing assessed by 
a Madsen tympanometer. At entry, patients were placed on a regimen of 
antibiotic and pseudoephedrine or placebo for two weeks. The decongestant 
or placebo was continued for an additional two to four weeks in those 
patients manifesting serous otitis media at the end of their two week 
course of antibiotic therapy. The authors concluded that by clinical 
exam and tympanometry, there was no significant change in either 
prevention or treatment of serous otitis media with an oral decongestant, 
and, for male patients or those with allergy or prior serous otitis 
media, the use of a decongestant slowed their recovery from serous 
otitis media. The authors further suggest that the lack of therapeutic 
benefit might have been attributable to inadequate nasal vasoconstriction 
afforded by the prescribed doses of decongestant, or by rebound nasal 
congestion exacerbating an underlying obstruction of the eustachian 
tube. 
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Randall and Hendley surmised that although antihistamine-decongestant 
products conferred no benefit to children with established otitis media, 
these agents might prevent the development of otitis in children with 
upper respiratory tract infection by maintaining the patency of the 
eustachian tube. One hundred and four preschool age children were 
treated prospectively during colds with a mixture of brompheniramine 
and phenylpropanolamine or placebo. Otitis media was diagnosed on the 
basis of clinical criteria. The antihistamine-decongestant was 
concluded to be ineffective in preventing otitis media as 6.4% of 
patients with colds treated with the study drug and 5.8% of patients with 
colds treated with placebo subsequently developed otitis media. 
The present investigation demonstrated that the presence of nasal 
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congestion and middle ear effusion could be appreciably affected by 
the administration of Naldecon , but it failed to confirm a therapeutic 
benefit clearly attributable to the antihistamine-decongestant mixture 
in altering the course of otitis media. Seventy-nine patients with 
acute otitis media with effusion were selected from a homogeneous sample 
population for all biographical data analyses performed. 
Compliance with the prescribed medications was uniformly high 
throughout the investigation and correlational analyses verified that 
outcome as determined both by the physicians' examination and the 
audiologists' evaluation of the tympanograms was unaffected by disparities 
in the patients' drug consumption. 
14 
Work done by Shurin et al demonstrated that persistent middle ear 
effusion was a frequent sequel to otitis media occuring in up to 55% of 
the subjects studied, and by life table analysis documented that otitis 
media is more likely to be persistent in children less than 24 months 
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of age and in those who are white. Olson and associates' study 
revealed that males as a group were more prone to develop serous otitis 
media than females as a late complication of acute otitis media. 
Although race was not an intentionally controlled variable in this 
investigation (all children were white), correlational analysis failed to 
uncover any significant relationships between age, sex, or number of 
prior episodes of otitis media and therapeutic outcome concluded by 
the physicians and audiologists. 
Symptomatic relief of cough and earache was not appreciably affected 
by the addition of an antihistamine-decongestant product to the 
antibiotic regimen. On the average, Naldecon treated patients 
complained of earache for an average 0.2 days less than the placebo 
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treated patients, and cough in the Naldecon treated patients resolved 
approximately 1,8 days sooner than in the placebo treated subjects. 
These differences were not statistically significant. Such ancillary 
complaints might best be treated with other adjunctive agents, including 
antipyretic-analgesics and antitussives as needed. 
Congestion in this population was a common ancillary complaint 
occuring in 83% of the patients overall. The administration of an 
antihistamine-decongestant led to the attenuation of this symptom 
approximately three days earlier than if the patients received 
antibiotic alone (p<0.05); the Naldecon patients were symptom free 
after 5.7 days in contrast to the placebo patients who were symptom 
free after 8.5 days. 
Evidence that nasal congestion might represent an anatomic barrier 
to proper drainage of the middle ear via the eustachian tube is 
offered by correlational analysis. The data demonstrate a significant 
correlation between the presence of effusion at day 14 and persisting 
congestion, thereby suggesting that early relief of nasal congestion 
might help to promote resolution of middle ear fluid accretion. Figure 
6 illustrates the relationship between nasal congestion and middle 
ear effusion. 
That a significant correlation should exist between the presence 
of congestion and an unsatisfactory physical exam at day fourteen 
suggests one of two possibilities: 1) nasal congestion was associated 
with an abnormal tympanic membrane as examined by pneumatic otoscopy, or 
2) the physicians' evaluation of the integrity of the middle ear anatomy 
was biased by the presence or absence of nasal congestion. It is 
interesting to point out that as the investigation neared completion, one 
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of the pediatricians remarked that he could identify which of his 
patients had received Naldecon by simply examining the patient for 
rhinitis. 
By serial tympanometry the physical characteristics of the ears 
tested were not significantly different between the two groups. 
Employing a modification of the criteria published by Paradise et al^ 
the tympanograms obtained in both treatment groups had low peak middle 
ear air pressures initially (less than -250 mm water) and low compliance. 
Over a fourteen day period the curves shifted toward an average peak 
middle ear air pressure of between -174 and -112 mm water and the 
compliances recorded increased almost two-fold. This trend was noted to 
occur in both groups as a function of time and the magnitude of change 
was not significant between the two groups. Although the average peak 
middle ear pressures measured at day fourteen for both groups would be 
construed as abnormal by the guidelines of Paradise et al^ and warrant 
further follow-up for otologic disease, interpretation of the tympanograms 
as specifically diagnostic of middle ear effusion was accomplished by 
employing the criteria of Beery and associates.^ Beery*s group demonstrated 
with myringotomy and tympanometry that in 70 patients studied, high 
negative middle ear pressure was not necessarily a reliable indicator 
of middle ear effusion. Instead, a combination of pattern classification 
and susceptance criteria enabled correct prediction of effusion in 93% 
of the patients studied. By these modified guidelines, it was evident 
from this investigation that the presence or absence of middle ear 
effusion was not significantly different for both groups upon entry into 
the study, and again at day seven of the study. At day fourteen 
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however, 26.7% of the Naldecon subjects compared to 48.6% of the 
placebo subjects had tympanometric criteria for effusion and this 
result approached statistical significance (p=0.07). Concealed 
within this finding is the discovery that patients given antibiotic 
and Naldecon were less likely to have evidence for right middle ear 
effusion after 14 days than patients given antibiotic alone (p^0.05). 
The clinical relevance of this finding was not readily apparent and 
remained obscure in view of the pediatricians' and audiologists1 
closely correlated agreement on therapeutic outcome. By the physicians' 
and audiologists' analyses, eleven and ten patients respectively were 
evaluated as unsatisfactory in the Naldecon group while only eight 
patients met tympanometric criteria for middle ear effusion. These 
results represent a discrepancy of approximately 10% between clinical 
assessment and tympanometry. For the placebo group, the physicians and 
audiologists evaluated 16 and 18 patients respectively as unsatisfactory, 
while 17 patients met tympanometric criteria for middle ear effusion. 
These results represent a discrepancy in agreement of approximately 6%. 
The number of subjects at issue is small, but the evident disagreement 
should point out the interpretive weaknesses of tympanometry. The 
work of Beery et al^ documents that in 7% of the patients evaluated, 
middle ear disease may not be reliably qualitated. McCandless and 
Thomas compared the diagnostic agreement of tympanometry, otoscopy, and 
audiometry in 730 patients and demonstrated 93% agreement between 
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tympanometry and otoscopy. A 7% margin of error, if also applicable 
here, could conceivably explain our inability to entirely relate the 
presence of middle ear effusion by tympanometry to therapeutic outcome 
or explain why right ears are less prone to persistent middle ear 
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effusion than left ears. 
Tympanometry may be a more accurate method of detecting middle 
ear effusion than audiometry.^ Bluestone and associates"^ have 
shown approximately half of the patients they studied with normal 
hearing also had middle ear effusion. Unfortunately, the functional 
impairment accompanying middle ear effusion remains unknown and still 
remains to be elucidated, perhaps through the interventions of 
33 37 
audiometry. ' Until such data become available it is possible 
that patients with middle ear effusion demonstrated by tympanometry 
could unnecessarily arouse the therapeutic inclinations of their 
attending physicians should this technique become the primary method for 
detecting middle ear disease. 
That between 37 and 46% of all patients studied here had an 
unsatisfactory response and required further follow-up or therapy is 
disturbing. The 20 to 50 mg/kg/day dosage of amoxicillin prescribed 
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was selected in accord with the manufacturer's product recommendations. 
This dose may have been inadequate to completely eradicate the underlying 
infection. McCracken and Eichenwald currently recommend using 
50 mg/kg/day of amoxicillin for otitis media, and to obviate the risk 
of infection due to beta-lactamase producing hemophilus strains, adding 
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erythromycin or a sulfonamide to the regimen. Aronovitz has 
achieved clinical and bacteriological cure in 96% of patients with 
otitis media by prescribing a dosage of between 16 and 70 mg/kg/day 
of amoxicillin. Our cure rate might have been greater had we used 
a higher dose of amoxicillin. 
CONCLUSION 
This investigation has systematically examined the therapeutic 
effects of an antihistamine-decongestant mixture adjunctive to 
antibiotic therapy in acute otitis media with effusion. 
The results reported show that the use of Naldecon in conjunction 
with an appropriate antibiotic is an efficacious regimen for treating 
the nasal rhinitis which frequently accompanies acute otitis media 
with effusion. The importance of this finding is that persistent 
nasal congestion often portends persistent middle ear effusion, an 
omen of therapeutic failure. The mixture may also be beneficial for 
promoting resolution of middle ear effusion as diagnosed by tympanometry, 
although, clinically, neither the examining physicians nor the audiologists 
could ascribe any clear-cut therapeutic benefit to the Naldecon 
prescription. 
Our recommendation is that Naldecon may be useful in the doses 
outlined herein for pediatric patients presenting with acute otitis 
media with effusion and nasal rhinitis. Although we can't responsibly 
comment at this time on the product's propensity for attenuating 
middle ear effusion, we do feel that patient comfort should not be 
sacrificed until further research is pursued. We also recommend that 
the dosage of amoxicillin (Polymox ) prescribed for otitis media be 
50 mg/kg/day. 
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Table 1. Dosages of Naldecon dispensed to Treatment Group I patients. 












Child's Body Weight R Volume of Naldecon dispensed 
6 - 9 kg 1.5 ml four times daily 
10 - 12 kg 2.0 ml four times daily 
13 - 14 kg 2.5 ml four times daily 
15 - 16 kg 3.0 ml four times daily 
17 - 18 kg 3.5 ml four times daily 
19 - 20 kg 4.0 ml four times daily 
21 - 22 kg 4.5 ml four times daily 
23 - 24 kg 5.0 ml four times daily 
25 - 26 kg 5.5 ml four times daily 
27 - 28 kg 6.0 ml four times daily 
29 - 30 kg 6.5 ml four times daily 
31 - 32 kg 7.0 ml four times daily 
33 - 34 kg 7.5 ml four times daily 
35 - 36 kg 8.0 ml four times daily 
37 — 39 kg 9.0 ml four times daily 
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Table 2. Dosages of amoxicillin suspension (Polymox ) prescribed for 
all study patients. Amounts are based on 20 - 50 mg/kg/day amoxicillin 
in three divided doses. 
Child's body weight Total daily dose Total daily dose/kg body weight 
5 - 9 kg 225 mg 25 - 45 mg 
10 - 15 kg 375 mg 25 - 37 mg 
16 - 20 kg 525 mg 26 - 33 mg 
21 - 25 kg 675 mg 27 - 32 mg 
26 - 35 kg 750 mg 21 - 28 mg 
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Table 3. Sample page from daily patient diary. 
For completion of out evaluation, we would appreciate it if you would 
complete the following form daily. Please post the form on your cabinet 
or refrigerator as a reminder. Questions apply only to this illness. 
Day Number One of Treatment 
1) Does the patient continue to have a fever? yes no 
never had a fever 
2) Does the patient still complain of earache? yes no 
never had an earache 
3) Does the patient still have a cough? yes no 
never had a cough 
4) Is the patient still congested or yes no 
troubled by a cold? never was congested 
5) Is the patient irritable? less irritable more irritable 
same never irritable 
6) Is the patient sleepy? less sleepy more sleepy same 
7) Have you given the medication as directed? yes no 
How many doses missed 
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Table 4. Experimental variables employed in missing value correlation 
statistical analysis. 
1. Treatment Group assignment. 
2. Patient randomization number. 
3. Patient sex. 
4. Patient age. 
5. Number of prior episodes of otitis media. 
6. Number of days symptomatic with cough. 
7. Number of days symptomatic with congestion. 
p 
8. Number of doses of Naldecon /placebo missed in study days one 
through seven. 
9. Number of doses of amoxicillin missed in study days one through 
seven. 
10. Number of doses of Naldecon /placebo missed in study days eight 
through fourteen. 
11. Number of doses of amoxicillin missed in study days eight through 
fourteen. 
12. Therapeutic response (satisfactory or unsatisfactory) as determined 
by physician. 
13. Left ear peak pressure recorded by initial tympanogram. 
14. Right ear peak pressure recorded by initial tympanogram. 
15. Left ear compliance recorded by initial tympanogram. 
16. Right ear compliance recorded by initial tympanogram. 
17. Left ear peak pressure recorded by tympanogram on day seven. 
18. Right ear peak pressure recorded by tympanogram on day seven. 
19. Left ear compliance recorded by tympanogram on day seven. 
20. Right ear compliance recorded by tympanogram on day seven. 
21. Left ear peak pressure recorded by tympanogram on day fourteen. 
(continued) 
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22. Right ear peak pressure recorded by tympanogram on day fourteen. 
23. Left ear compliance recorded by tympanogram on day fourteen. 
24. Right ear compliance recorded by tympanogram on day fourteen. 
25. Classification of left ear tympanogram initially. 
26. Classification of right ear tympanogram initially. 
27. Classification of left ear tympanogram at day seven. 
28. Classification of right ear tympanogram at day seven. 
29. Classification of left ear tympanogram at day fourteen. 
30. Classification of right ear tympanogram at day fourteen. 
31. Presence or absence of effusion in left ear initially. 
32. Presence or absence of effusion in right ear initially. 
33. Presence or absence of effusion in left ear at day seven. 
34. Presence or absence of effusion in right ear at day seven. 
35. Presence or absence of effusion in left ear at day fourteen. 
36. Presence or absence of effusion in right ear at day fourteen. 
37. Evaluation of left ear tympanogram by audiologists at day seven. 
38. Evaluation of right ear tympanogram by audiologists at day seven. 
39. Evaluation of left ear tympanogram by audiologists at day fourteen. 
40. Evaluation of right ear tympanogram by audiologists at day fourteen. 
Table 5. Biographical characteristics of the study population. 
Age (months) Number of prior episodes of otitis media Sex of the cohorts 
Naldecon Placebo Naldecon Placebo Naldecon Placebo 
32.7 35.4 X 1.8 1.8 11 19 
25.6 25.4 SD 2.1 1.6 19 16 
30 35 n 30 35 30 35 
t = 0.44 t = 0.07 X 2 = 1.36 
df = 63 df = 63 df = 1 
p>0.05 p>0.05 p>0.05 
w Ui 
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Table 6. Frequency distribution of middle ear effusion by 











X* = 0.10 
df = 1 






Table 7. Frequency and duration (days) of earache reported 
by patients three years of age and older. 
Naldecon Group Placebo Group 
X 2.5 . 2.7 
SD 1.5 2.5 
n 6 12 
t = 1.73 
df - 16 
p > 0.05 
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Table 8. Frequency and duration (days) of cough as an 
ancillary symptom in acute otitis media. 
Naldecon Group Placebo Group 
X 6.0 7.8 
SD 3.0 5.0 
n 18 24 
t = 1.32 
df = 40 
p > 0.05 
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Table 9. Frequency and duration (days) of nasal congestion as 
an ancillary symptom in otitis media. 
Naldecon Group Placebo Group 
X 5.7 8.5 
SD 3.8 4.9 
n 24 30 
t = 2.31 
df = 52 
p < 0.05 
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Table 10. Frequency distribution of patients concluded to 
be noncompliant and compliant with their prescribed medications. 
Naldecon Group Placebo Group Total 
compliant 27 32 59 
noncompliant 3 3 6 
30 35 65 
X 2 = 0.81 
df = 1 
p > 0.05 
Table 11. Summary of correlations performed between medication compliance and experimental 














1. Doses of Naldecon /placebo missed in days one through seven and 
physician's exam at day fourteen. 
2. Doses of Naldecon /placebo missed in days eight through fourteen 
and physician's exam at day fourteen. 
3. Doses of amoxicillin missed in days one through seven and 
physician's exam at day fourteen. 
4. Doses of amoxicillin missed in days eight through fourteen and 
physician's exam at day fourteen. 
5. Doses of Naldecon /placebo missed in days one through seven and 
presence of left ear effusion at day fourteen. 
6. Doses of Naldecon /placebo missed in days eight through fourteen 
and presence of left ear effusion at day fourteen, p 
7. Doses on Naldecon /placebo missed in days one through seven and 
presence of right ear effusion at day fourteen. 
Doses of Naldecon /placebo missed in days eight through fourteen 
and presence of right ear effusion at day fourteen. 
Doses of amoxicillin missed in days one through seven and 
presence of left ear effusion at day fourteen. 
10. Doses of amoxicillin missed in days eight through fourteen and 
presence of left ear effusion at day fourteen. 





















Table 11. Summary of correlations performed between medication compliance and experimental 














1. Doses of Naldecon /placebo missed in days one through seven and 
physician's exam at day fourteen. 
2. Doses of Naldecon /placebo missed in days eight through fourteen 
and physician's exam at day fourteen. 
3. Doses of amoxicillin missed in days one through seven and 
physician's exam at day fourteen. 
4. Doses of amoxicillin missed in days eight through fourteen and 
physician's exam at day fourteen. 
5. Doses of Naldecon /placebo missed in days one through seven and 
presence of left ear effusion at day fourteen, p 
6. Doses of Naldecon /placebo missed in days eight through fourteen 
and presence of left ear effusion at day fourteen. 
7. Doses on Naldecon /placebo missed in days one through seven and 
presence of right ear effusion at day fourteen, p 
8. Doses of Naldecon /placebo missed in days eight through fourteen 
and presence of right ear effusion at day fourteen. 
9. Doses of amoxicillin missed in days one through seven and 
presence of left ear effusion at day fourteen. 
10. Doses of amoxicillin missed in days eight through fourteen and 























Correlation r value frequency 
11. Doses of amoxicillin missed in days one through seven and -0.02 62 
presence of right ear effusion at day fourteen. 
12. Doses of amoxicillin missed in days eight through fourteen 0.16 62 
and presence of right ear effusion at day fourteen. 
* r ^  0.25 significant at the 0.05 level. 
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Table 12. Classification of left and right tympanograms 
in the study. 
upon entry 
Left Ear 
Naldecon Group Placebo Group 
Class I 29 (96.7%) 32 (91.4%) 
Class III 1 (3.3%) 3 (8.6%) 
30 35 
X 2 - 0.13 
df = 1 
p > 0.05 
Right Ear 
Naldecon Group Placebo Group 
Class I 29 (96.7%) 32 (91.4%) 
Class III 1 (3.3%) 3 (8.6%) 
30 35 
X 2 = 0.13 
df = 1 









Table 13. Classification of left and right ear tympanograms at 













30 35 65 
X = 0.02 
df = 1 













30 35 65 
X* = 0.01 
df = 1 
p > 0.05 
Table 14. Classification of left and right ear tympanograms at 
day fourteen of the study. 
Left Ear 
Naldecon Group Placebo Group Total 
Class I 29 (96.7%) 35 (100%) 64 
Class III 1 (3.3%) 0 1 
30 35 65 
X 2 = 0.01 
df = 1 
p > 0.05 
Right Ear 
Naldecon Group Placebo Group Total 
Class I 29 (96.7%) 35 (100%) 64 
Class III 1 (3.3%) 0 1 
30 35 65 
X 2 = 0.01 
df = 1 
p > 0.05 
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Table 15. Frequency of left and right ear effusion by tympanometry 













30 35 65 
X = 2.05 
df = 1 













30 35 65 
X* « 0.37 
df = 1 
p > 0.05 
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Table 16. Frequency of middle ear effusion by tympanometry 
at day seven of the study. 
Naldecon Group Placebo Group Total 
Effusion 14 (46.7%) 19 (54.3%) 33 
No Effusion 16 (53.3%) 16 (45.7%) 32 
30 35 65 
X 2 = 0.36 
df = 1 
p > 0.05 
Table 17. Frequency of left and right ear effusion by 
at day seven of the study. 
tympanometry 
Left Ear 
Naldecon Group Placebo Group Total 
Effusion 10 (33.3%) 14 (40%) 24 
No Effusion 20 (66.7%) 21 (60%) 41 
30 35 65 
X 2 = 0.31 
df = 1 
p > 0.05 
Right Ear 
Naldecon Group Placebo Group Total 
Effusion 12 (40%) 17 (48.6%) 29 
No Effusion 18 (60%) 18 (51.4%) 36 
30 35 65 
X 2 = 0.48 
df = 1 
p >0.05 
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Table 18. Frequency of middle ear effusion by tympanometry 
at day fourteen of the study. 
Naldecon Group Placebo Group Total 
Effusion 8 (26.7%) 17 (48.6%) 25 
No Effusion 22 (73.3%) 18 (51.4%) 40 
30 35 65 
X 2 = 3.27 
df = 1 
p = 0.07 
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Table 19. Frequency of left and right ear effusion by tympanometry 













30 35 65 
X = 0.94 
df = 1 














X 2 = 4.77 
df = 1 
p < 0.05 
65 
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Table 20. Therapeutic response determined by the audiologists' 
evaluation of day fourteen tympanograms. 
Naldecon Group Placebo Group Total 
Satisfactory 20 (66.7%) 17 (48-6%) 37 
Unsatisfactory 10 (33.3%) 18 (51*4%) 28 
30 35 65 
X 2 = 2.15 
df = 1 
p > 0.05 

Table 22. Peak middle ear pressures recorded by tympanometry. 
Initial left middle ear pressure 
Initial right middle ear pressure 
Day seven left middle ear pressure 
Day seven right middle ear pressure 
Day fourteen left middle ear pressure 
Day fourteen right middle ear pressure 
Naldecon Group 
-344 + 109 mm water 
-294 + 155 mm water 
-179 + 153 mm water 
-207 + 170 mm water 
-122 + 158 mm water 
-112 + 149 mm water 
Placebo Group 
-274 + 164 mm water 
-282 + 179 mm water 
-182 + 191 mm water 
-195 + 182 mm water 
-152 + 172 mm water 





Probability F exceeded 
0.00 
Table 23. Middle ear compliances recorded by tympanometry. 
Initial left ear compliance 
Initial right ear compliance 
Day seven left ear compliance 
Day seven right ear compliance 
Day fourteen left ear compliance 
Day fourteen right ear compliance 
Naldecon Group 
0.51 + 0.94 mmhos 
0.57 + 0.83 mmhos' 
0.95 + 0.86 mmhos 
0.84 + 0.89 mmhos 
0.98 + 0.80 mmhos 
1.11 + 0.82 mmhos 
Placebo Group 
0.55 + 0.75 mmhos 
0.45 + 0.55 mmhos 
0.80 + 0.73 mmhos 
0.73 + 0.76 mmhos 
0.96 + 0.92 mmhos 
0.96 + 1.03 mmhos 
df F Probability F exceeded 
Time 2 14.53 0.00 
m -t-
Table 24. Summary of "correlations between population characteristics and therapeutic outcome. 
Correlation 
1. Age of the patient and physician's exam at day fourteen 
2. Age of the patient and left middle ear effusion at day fourteen 
3. Age of the patient and right middle ear effusion at day fourteen 
4. Age of the patient and the audiologists' evaluation of the final 
left ear tympanogram 
5. Age of the patient and the audiologists' evaluation of the final 
right ear tympanogram 
6. Sex of the patient and physician's exam at day fourteen 
7. Sex of the patient and left middle ear effusion at day fourteen 
8. Sex of the patient and right middle ear effusion at day fourteen 
9. Sex of the patient and the audiologists' evaluation of the final 
left ear tympanogram 
10. Sex of the patient and the audiologists' evaluation of the final 
right ear tympanogram 
11. Number of prior episodes of otitis media and physician's exam at 
day fourteen 
12. Number of prior episodes of otitis media and left middle ear 





























Correlation r value 
13. Number of prior episodes of otitis media and right middle ear -0.15 
effusion at day fourteen 
14. Number of prior episodes of otitis media and the audiologists' -0.13 
evaluation of the final left ear tympanogram 
15. Number of prior episodes of otitis media and the audiologists' -0.13 
evaluation of the final right ear tympanogram 
* 
r } 0.25 significant at the 0.05 level 
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Figure 1. Tympanogram Obtained from the Left Ear of a Nine-Year-Old 
Girl with Normal Results on Otoscopic Examination and No History 
of Middle-Ear Disease (9) . 
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Figure 2. Schematic Drawing of Components of the Otoadmittance Meter. 
OSCILLATOR AMPLIFIER SPEAKER 
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Figure 3. Phase and Vector Diagrams of Acoustic Admittance, Conductance, 




0* 180* 360* 1 l 0' 180 360 1 1 
The phase diagrams (al-3, bl-3, and cl) show the sound signals produced 
and monitored by the otoadmittance meter. In these phase diagrams the 
vertical axis represents acoustic energy, and the horizontal axis time. 
The horizontal axes are drawn at the energy level of zero. 
The vector diagrams (a4, b4, and c2) represent each signal by an arrow 
in which length is a function of mean energy level and direction is 
a function of the phase of the sine-wave signal represented. The 
otoadmittance meter produces signals of either 220 or 660 Hz (cycles 
per second). The microphone signals in examples a and b have the same 
frequency and energy levels, but differ by a phase angle (jf) of 90. 
Acoustic admittance (Y) is a function of the root mean square (rms) 
voltage that must be applied to the speaker leads to produce an 85-decibel 
sound level in the ear canal. Y is measured by a voltmeter directly 
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from the rms voltage supplied to the speaker. 
One measures the phase angle (&) by which the speaker and microphone 
signals differ by multiplying these signals. Signal a3 is the product 
of al x a2. This product has its maximum mean value when ef = 0*(example 
a). Signals differing by gf = 90*(bl and b2) have a product (b3) whose 
mean value is 0. 
Acoustic conductance (G) and susceptance (B) are the rectangular 
components of Y (example c2). The vector of G is in phase with the 
speaker signal, whereas that of B is 90 out of phase. Example c 
shows the general case in which the speaker and microphone signals 
differ both in mean energy level and in phase = 37 ). The product 
of the two signals is intermediate in mean value between the maximal 
value produced when gf = 0 (example a) and 0, which is found when & = 90 
(example b). The values -of B and G is each case are computed by the 
otoadmittance meter with the measured values of Y and 0 and the formulas 
B = Y sin & and G = Y cos xS. 
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Figure 5. Block diagram of the split-plot analysis of variance 
performed for all tympanogram measurements. 
B1 B1 B2 B 2 B3 B3 
C1 C2 C1 C 2 C1 C2 
A1 S1 S1 S1 S1 S1 S1 
A 2 S 2 S2 S2 S2 S2 S, t 
A^ = Naldecon group patients 
A^ = Placebo group patients 
B^ = Tympanometric measurement initially 
B^ = Tympanometric measurement at day seven 
B^ = Tympanometric measurement at day fourteen 
C^ = Left ear measurement 
C^ = Right ear measurement 
S^  = Subject number 
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s^  30 
20 
10 
R middle ear effusion in Naldecon group 
middle ear effusion in placebo group 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
STUDY DAY 
Shaded area = nasal congestion in Naldecon group 
Light area = nasal congestion in placebo group 
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APPENDIX I: 
USE OF AN ANTIHISTAMINE/DECONGESTANT IN CONJUNCTION 
WITH AN ANTIINFECTIVE IN TREATING OTITIS MEDIA 
CONSENT FORM 
We are conducting a study to determine the best drugs to use 
in treating inflammation of the middle ear (otitis media). Because 
your child has such an inflammation he/she has been invited to participate 
in this study. The purpose of the study is to determine if the addition 
of an antihistamine/decongestant combination to standard antiinfective 
therapy results in a more rapid clearing of middle ear infection. If 
you consent to participate your child will be placed in one of two 
groups. All children will initially receive standard antiinfective 
drugs. In addition, children in one group will receive a standard 
antihistamine/decongestant combination, and children in the second 
group will receive a syrup with no active drug which will look the 
same as the antihistamine/decongestant. 
Antihistamine/decongestant drugs are sometimes used in treating 
middle ear infections in conjunction with antiinfectives in the belief 
that they help the symptoms respond more rapidly. But we do not 
know if they are really helpful. Antihistamines may produce drowsiness 
in some children and decongestants have produced a mild jitteriness. 
Three hearing tests will be performed on your child during the study. 
The first test will be performed at the first clinic visit, you will 
then be asked to return to the clinic in seven days to have a second 
hearing test performed. At the completion of the study (14 days after 
your initial visit) the pediatrician will examine your child and a 
third hearing test will be performed. At that time an evaluation of 
your child's response to therapy will be determined and appropriate 
recommendations will be made. You will also be asked to complete a 
questionnaire that will enable us to evaluate your perception of your 
child's response to the treatment. 
Please read and sign the following statement. 
I have had the opportunity to ask questions about the study and I 
have received acceptable answers. I understand that I may withdraw 
from this study for any reason, and that my child will still receive 
the best standard treatment for his/her condition. 
WITNESS SIGNATURE OF PARENT OR GUARDIAN 
INVESTIGATOR SIGNATURE OF PATIENT (IF APPLICABLE) 
DATE 
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APPENDIX II: DATA 
The biographical characteristics, duration of symptoms, tympanogram 
measurements, and therapeutic responses recorded for each patient are 
reported. Treatment Group I represents the Naldecon treated patients 
and Treatment Group II represents the placebo treated patients. 
TREATENT CROUP 
SUBJECT ACE PHTOR EPISODES SEX DURATION DURATION DURATION DRUC DOSES MISSED RESPONSE HY 66 
NUMBER (MONTHS) OTITIS MEDIA EARACHE COUCH CONGESTION DAYS 1-7 DAYS 8-14 M.U.'s EXAM (DAYS) (DAYS) (DAYS) NuUI Amx NaUl Amx 
3 12 1 M — 6 6 0 0 1 0 Unsatisf actory 
4 29 4 F — 7 6 2 2 2 2 Unsatisfactory 
10 30 0 F — 3 3 3 2 7 5 Unsatisfactory 
U 10 0 F — 9 10 2 1 1 0 Unsatisfactory 
14 12 0 F — 7 7 0 0 1 0 Unsatisfactory 
16 46 0 F NO QUESTIONNAIRE RETURNED Unsatisfactory 
17 20 6 M — 4 6 5 1 6 1 Satisfactory 
19 8 0 F — 7 8 1 0 4 0 Unsatisfactory 
22 7.5 3 F NO QUESTIONNAIRE RETURNED Satisfactory 
24 17 0 F 7 14 0 0 3 1 Satisfactory 
39 LOST TO FOLLOW-UP 
40 DROPPED DUE TO ADVERSE DRUG REACTION 
41 32 0 M — 7 2 1 0 2 0 Satisfactory 
42 DROPPED DUE TO WORSENING OF DISEASE 
44 DROPPED DUE TO FAILURE TO COMPLY WITH PROTOCOL 
46 60 0 M 3 0 3 6 0 6 0 Satisfactory 
49 LOST TO FOLLOW-UP 
53 59 5 F 0 0 2 3 0 2 0 Satisfactory 
56 105 0 M 1 0 2 1 0 2 1 Satisfactory 
57 63 1 F 5 0 3 3 0 0 0 Satisfactory 
59 13 4 M — 6 8 0 0 0 0 Satisfactory 
60 71 6 F 0 5 5 0 0 0 0 Unsatisfactory 
61 25 6 F — 5 5 0 0 0 0 Satisfactory 
65 LOST TO FOLLOW-UP 
66 48 4 M 0 0 0 0 0 0 0 Satisfactory 
67 7 0 F — 0 0 1 0 3 3 Satisfactory 
69 LOST TO FOLLOW-UP 
70 11 2 F — 0 1 0 0 0 0 Satisfactory 
72 58 1 F 0 2 2 5 0 3 0 Satisfactory 
74 26 4 F — 14 14 1 0 0 0 Unsatisfactory 
75 12 1 M — 5 5 0 0 2 0 Satisfactory 
76 72 1 M 1 0 0 0 0 0 0 Satlsfactory 
79 7 3 F — 9 5 0 0 1 0 Satisfactory 
82 11 0 F — 0 13 1 0 0 0 Unsatisfactory 
86 LOST TO FOLLOW-UP 
87 LOST TO FOLLOW-UP 
89 60 0 M 2 4 4 1 0 0 0 Satisfactory 
91 12 0 F — 0 0 1 0 0 0 Satisfactory 
95 DROPPED TO WOU SENINC OF DISEASE 
98 36.5 0 F 3 1 3 0 0 0 0 Unsatisfactory 
TREATMENT CROUP 1 
SUBJECT INITIAL TWANOCRANS  DAY 7 TYHPANOCRAMS DAY 14 TYMPANOGRAMS NUMBER mm H-0 mm HQS J I . O mmllOS _ " , m _ , 1 9 0 _ mmllOS 
"i R L ~ R L R~ L r" 1 R L ~ * R 
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3 -400 -400 0 0 -300 -325 1.25 1.25 -220 -ICO 2. 0 2. ,0 
4 -400 -400 0 0 -60 -40 0.75 0.50 -45 -90 0. 5 1. ,0 
10 -400 -400 0 0 -180 -200 2.30 2.00 -400 -400 0 0 
11 -400 -400 0 0.25 -400 -400 0.25 0.25 -400 -400 0 0 
14 -400 -140 0. ,25 1.20 -400 -180 0.20 1.75 -400 -140 0. ,20 1. .75 
16 -400 -240 0 0.25 -40 0 0.20 0.35 0 0 0. 20 0. ,50 
17 -400 -400 0. 25 0.25 -40 -40 1.00 1.00 +20 +20 1. 20 1. ,20 
19 -400 -200 0. 20 2.00 -200 -400 1.75 0.20 -60 -40 1. 00 1. ,00 
22 -400 -400 0 0 -100 -190 1.25 1.00 -40 -20 0. 75 0. ,75 
24 -400 -400 0 0 +40 -20 1.00 1.25 -80 -60 1. ,25 1. ,25 
39 LOST TO FOLLOW--UP 
40 DROPPED DUE TO ADVERSE DRUG REACTION 
41 -250 -250 1. 00 1.00 -30 +20 1.00 0.75 +20 +60 1. .00 1. ,00 
42 DROPPED DUE TO WORSENING OF DISEASE 
44 DROPPED DUE TO FAILURE TO COMPLY WITH PROTOCOL 
46 -400 +130 0 0.75 +20 0 0.70 0.75 +20 0 0. ,50 1. .00 
49 LOST TO FOLLOW--UP 
53 -340 -275 4. 75 4.0 -200 -145 4.25 4.20 +40 0 3. .25 3. .00 
56 +15 -75 1. 00 1.00 -30 0 1.00 0.50 -10 +20 1. ,70 0. .75 
57 -130 -160 0. 75 0.75 0 0 0.50 0.50 +10 0 0. ,50 0. .25 
59 -400 -400 0 0 -120 -400 0.75 0 -160 -125 1, .75 1. .50 
60 -400 -400 0 0 -400 -400 0 0 -400 -220 0. .20 1. .00 
61 -400 -400 0 0 -140 -200 2.00 2.00 -65 -25 1. .00 2. .00 
65 LOST TO FOLLOW--UP 
66 -240 -400 0. 80 0 -40 -45 0.75 0.50 -25 -80 0. .50 0, .50 
67 -400 -400 0 0 -125 -130 0.50 . 0.75 -40 -20 1. .00 1. ,00 
69 LOST TO FOLLOW--UP 
70 -400 -220 1. ,00 1.25 -160 -100 1.25 1.25 0 +40 2, .00 2, ,00 
72 -125 -130 1. 25 0.75 -80 -225 1.25 0.50 -180 -125 1. 00 0, .50 
74 -280 -150 1. 20 0.85 -140 -400 1.80 0 -400 -400 0 0 
75 -180 -400 1. ,50 0.25 -400 -400 0.20 2.00 0 -45 1, ,50 1, .50 
76 -400 -400 0 0 -70 + 25 0.25 0.20 -50 -140 0, .75 0 .50 
79 -400 -400 0. ,50 0.50 -400 -400 1.00 1.00 -400 -400 0, .20 0 .20 
82 -400 -400 1. ,00 1.00 -160 -400 1.00 0.50 -100 -400 1, .20 0 .25 
86 LOST TO FOLLOW--UP 
87 LOST TO FOLLOW--UP 
89 -400 -100 0 1.00 -400 -400 0 0 -250 -70 0, .50 X .75 
91 -400 -400 0 0 -400 -400 0.25 0.25 -40 -10 2 .75 3 .00 
95 DROPPED DUE ' 10 WORSENING OF DISEASE 
98 -400 -400 0 0 -400 -400 0.25 0 0 -40 1 .00 2 .00 





I. R L R 
DAY 7 TYMI'ANOCKAMS 
CLASS EFFUSION 
L R L R 
DAY 14 TYMPANOCRAMS 
CLASS EFFUSION 




3 I I + + I I - - - - S s 
4 I I + + I I - - I I - - S s 
10 I I + + I I - - I I + + u u 
11 I I + + I I + + 1 1 + + U u 
14 I I + - I I + - I I + - U u 
16 III I + + III III + + III III + + u u 
17 I 1 + + I I - - I I - S s 
19 I I + - I I - + I I - - S s 
22 I I + + I I - - I I - - s s 
24 I I + + I I - - I I - - s s 
41 I I + + I I - - I I - - s s 
46 I I + + I I - - I I - - s s 
53 I I - - I I - - I I - - s s 
56 I I - - I I - - I I - - s s 
57 I I - - I I - - I I - - s s 
59 I I + + I I - + I I - - s s 
60 I I + + I I + + I I + - u s 
61 I I + + I I - - I I - - s s 
66 I I - + I I - - I I - - s s 
67 I I + + I I - - I I - - s s 
70 I I + - I I - - I I - - s s 
72 I I - - I I - - I I - - u s 
74 I I - - I I - + I I + + u u 
75 I I - + I I + - I I - - s s 
76 + + I I + + I I - - s s 
79 I I + + I I + + I I + + u u 
82 I I + + I I - + I I - + s u 
89 I I + - III I + + I I - - u s 
91 I I + + I I + + I I - - s s 
98 I III + + I I + + I I - - s s 
(+) denotes presence of effusion 
(-) denotes absence of effusion 
S) denotes satisfactory response 
U) denotes unsatisfactory response 
TKFATOKNT CKOOP_U • 
SUBJECT ACE PRIOR EPISODES SEX DURATION DURATION DURATION DRUG DOSES HISSED RESPONSE BY 
NUMBER (MONTHS) OTITIS MEDIA EARACHE COUCH CONGESTION DAYS 1-7 DAYS 8-1A M.I), 'a EXAM 
(DAYS) (DAYS) (DAYS) Nuld Amx Nil Id Anns 
1 6 1 M 7 5 2 0 2 0 Satisfactory 
2 16 4 M — 1 1 0 0 2 0 Satlflf actory 
5 42 0 M 1 5 3 2 2 1 1 Unsatisfactory 
6 87 0 F 1 0 9 1 1 1 0 Satisfactory 
8 53 2 F 0 11 11 0 0 2 0 Satisfactory 
9 15 3 M — NO QUESTIONNAIRE RETURNED Satisfactory 
15 17 1 M — 0 1 1 0 0 0 Satisfactory 
20 80 0 M 1 0 0 0 0 0 0 Satisfactory 
27 12 1 F — 9 14 1 0 0 0 Unsatisfactory 
43 16 4 M — 4 4 3 0 1 0 Satisfactory 
45 DROPPED DUE TO FAILURE TO COMPLY WITH PROTOCOL 
47 72 4 M 0 12 12 0 0 0 0 Satisfactory 
48 8 0 F — 4 0 1 1 1 2 Unsatisfactory 
50 23 2 M 0 2 I 1 2 2 Unsatisfactory 
51 LOST TO FOLLOW-UP 
52 45 .2 F 9 14 14 0 0 0 0 Unsatisfactory 
54 10 0 M — 14 14 4 0 4 0 Unsatisfactory 
55 26 1 F — 2 10 0 0 3 0 Unsatisfactory 
58 23 5 M — 0 13 1 0 3 0 Unsatisfactory 
62 81 0 M 4 0 8 2 0 5 0 Unsatisfactory 
63 7 0 F 0 8 1 0 2 0 Unsatisfactory 
64 33 2 M — 9 14 1 0 2 0 Satisfactory 
68 11 4 M — 1 4 1 0 3 0 Satisfactory 
71 13. 5 3 M — 14 14 1 0 4 0 Satisfactory 
73 31 0 F — 0 2 4 1 1 0 Satisfactory 
77 LOST TO FOLLOW-UP 
78 46. 5 1 F 1 6 6 0 0 0 0 Unsatisfactory 
80 9 4 F — 14 14 0 0 0 0 Satisfactory 
81 38 3 M 1 7 14 2 0 5 3 Unsatisfactory 
83 20 4 M — 5 4 2 2 2 1 Satisfactory 
84 81 1 F 3 3 4 3 2 2 1 Satisfactory 
85 38 2 F — 0 0 0 0 0 0 Satisfactory 
88 60. .5 0 F 2 3 14 0 0 1 0 Satisfactory 
90 LOST TO FOLLOW-UP 
92 14. .5 2 M — 14- 14 0 0 0 0 Unsatisfactory 
93 65 .5 0 F 1 14 14 2 0 6 0 Unsatisfactory 
94 65 1 F 6 14 6 1 1 4 4 Unsatisfactory 
97 17 .5 3 F — 1 3 0 0 0 0 Satlsfnc tory 
99 57 ,5 3 N 2 0 0 3 0 9 0 Unsatisfactory 

NIT1AL TYMI'ANtKJUANS 
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DAY 14 TYMPANOCKAMS 
I .ASS EFFUSION 
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( - ) 
denotes presence of effusion 
denotes absence of effusion 
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S) denotes sutlsfactury response 
U) denotes unsatisfactory response 
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methadone maintenance center), Salt Lake City, Utah, December 1979 to 
June 1979. 
3) Apprentice pharmacist, Skokie Valley Community Hospital, Skokie, 
Illinois, June 1976 to June 1978. 
4) Apprentice pharmacist, Gsell's Pharmacy, Highland Park, Illinois, 
February 1978 to July 1978. 
5) Crisis counselor, Metro-Help/The National Runaway Switchboard, 
Chicago, Illinois, July 1977 to July 1978. 
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PROFESSIONAL SOCIETIES 
1) American Society of Hospital Pharmacists, 1977 to present. 
2) Utah Society of Hospital Pharmacists, 1978 to present. 
3) Utah Pharmaceutical Association, 1978 to present. 
TEACHING EXPERIENCE 
1) Associate Research Instructor, University of Utah College of Pharmacy, 
July 1980 to present. 
2) Teaching Fellow, Adult Internal Medicine, University of Utah College 
of Pharmacy, fall quarter, 1979, and spring quarter, 1980. 
3) Teaching Fellow, Pediatrics, University of Utah College of Pharmacy, 
winter quarter, 1979. 
INVITED PRESENTATIONS 
1) "Drug therapy in the critically ill patient," to the University of Utah 
critical care program for critical care nursing, July, 1980. 
2) "Drug therapy in the elderly," to the Holy Cross Hospital Nurse's Program 
for Continuing Education, May, 1980. 
3) "Update in cardiovascular care: vasoactive drugs," to the LDS Hospital 
Housestaff, May, 1980. 
4) "Bolus vs. continuous administration of antibiotics: Fibrin penetration 
in bacterial endocarditis," Infectious Disease Grand Rounds, University 
of Utah Hospital, April, 1980. 
5) "Pharmacokinetics for everyday use," to the Utah Society of Hospital 
Pharmacists Therapeutics Conference, Hotel Utah, Salt Lake City, 
March, 1980. 
6) "Treatment of Gram Negative Septic Shock," to the University of Arizona 
College of Pharmacy, Tucson, Arizona, March, 1980. 
7) "Cimetidine in children," to the Departments of Gastroenterology, 
Salt Lake City Veterans Administration Hospital and University of Utah 
Hospital, March, 1980. 
8) "Management of the anemias," to the first year Pharm.D. Candidates, 
University of Utah College of Pharmacy, January, 1980. 
9) "Management of chronic obstructive pulmonary disease," to the fourth 
year pharmacy undergraduates, January, 1980. 
10) "Drug therapy in the terminally ill," to the Department of Pharmacy, 
Holy Cross Hospital, Salt Lake City, November 1979. 
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11) "Cimetidine in the treatment of pediatric gastroesophageal reflux: 
a pharmacologic and pharmacokinetic evaluation," to the Department 
of Pharmacy, University of Utah Hospital, October, 1979. 
12) "Drug use in the elderly," to the Nursing and Administrative Staff, 
Rocky Mountain Gerontology Center, Salt Lake City, May and July, 1979. 
13) "Monitoring quinidine therapy," to the Surgical Nursing Staff, 
University of Utah Hospital, April, 1979. 
14) "Cardiovascular agents," to the University of Utah Critical Care 
Program for Critical Care Nursing, October, 1978, and January, 1979. 
15) "Recognition and assessment of the drug abuser," to the Crisis Staff 
of Metro-Help, Chicago, Illinois, February, April, and July, 1978. 
RESEARCH ACTIVITIES 
1) "The use of an antihistamine-decongestant in conjunction with an 
antiinfective in treating acute otitis media." Funded by Bristol 
Laboratories ($7,000). 
2) "The pharmacokinetics and efficacy of cimetidine in maintaining gastric 
pH greater than six in patients following major thermal injury." 
Funded by Smith Kline and French Laboratories ($34,231). 
3) "Evaluation of the elimination half-life of cimetidine 14 days after 
major thermal injury." Funded by the University of Utah Research 
Committee ($900). 
4) "A home intravenous antibiotic therapy program." Submitted for funding 
to the 3-M Company ($34,800). 
PUBLICATIONS 
1) Moran DM: Over-Use of parenteral cimetidine, Drugs in Patient Care, 
University of Utah Health Sciences Center 1(6): 3, 1978. 
2) Moran DM: Metoprolol: A new beta-adrenergic blocking agent for 
hypertension, Drugs in Patient Care, University of Utah Health Sciences 
Center 1(5): 3, 1978. 
3) Moran DM: Aminoglycosides on the formulary: Amikacin restricted, 
Drugs in Patient Care, University of Utah Health Sciences Center 
1(5): 2, 1978. 
4) Yeh TL, Moran DM, Gorenstein S: (letter) Aminoglycoside dose 
calculations, American Journal of Hospital Pharmacy 35(8): 902, 1978. 
HONORS 
1) University of Utah Merit Scholarship, Department of Pharmacy Practice, 
1979 through 1980. 
2) 
3). 
University of Utah College of Pharmacy Dean's List, 1978 through 1980. 
Rho Chi, Professional Honor Society, 1980. 
Professional C-oals 
1) To promote the delivery of complete pharmacy services to hospitalized 
patients. 
2) To contribute to the profession of pharmacy through continued research 
and publication. 
3) To contribute to the education of all health professionals and students 
of the pharmaceutical sciences. 
4) To promote the growth of pharmacy through active involvement in the 
profession's national and local organizations. 
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